Molecular pathology and precision medicine for lung cancer

Giulio Rossi (Modena, Italy)

Source: International Congress 2017 – Precision medicine approaches in lung cancer

Session: Precision medicine approaches in lung cancer
Session type: Symposium
Number: 2884

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Giulio Rossi (Modena, Italy). Molecular pathology and precision medicine for lung cancer. International Congress 2017 – Precision medicine approaches in lung cancer

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Pathology and molecular biology of lung cancer Source: Annual Congress 2006 - PG19 - Thoracic oncology: diagnostic assessment of lung cancer Year: 2006
Molecular abnormalities and histopathology in lung cancer Source: ERS Research Seminar Year: 2015
Molecular imprint of lung cancer development Source: ERS Lung Science Conference 2017 Year: 2017
Development of an invasive 3D lung tumor model for oncological research Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013
Cytological diagnostics of lung cancer: our experience Source: Eur Respir J 2005; 26: Suppl. 49, 306s Year: 2005
Complexity of diagnostics of complicated lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 39s Year: 2004
Precision medicine for lung cancer: new targeted treatments Source: International Congress 2017 – Precision medicine approaches in lung cancer Year: 2017
The utility of bronchoscopically acquired tissue for successful lung cancer molecular profiling (LC-MP) Source: Annual Congress 2013 –Comfort, safety and effectiveness of bronchoscopy Year: 2013
Role of biomarkers for early detection of lung cancer and chemoprevention Source: Eur Respir J 2002; 19: 1151-1158 Year: 2002
Significance of expression of TGF-β in pulmonary metastasis in non-small cell lung cancer tissues Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015
Evolution in the diagnostic approach to lung cancer Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021
Molecular biomarkers for lung adenocarcinoma Source: Eur Respir J , 49 (4) 1601734; DOI: 10.1183/13993003.01734-2016 Year: 2017
Imaging techniques in lung cancer Source: Breathe 2011; 7: 338-346 Year: 2011
Challenges in molecular testing in lung cancer patients with advanced disease Source: International Congress 2016 – Lung cancer: latest developments in screening and patient management Year: 2016